Purchase this article with an account.
T. Das, IV, S. Basu, A. Kumari, S. Maitra, T. R. Padhi; Trends and Indications for Intravitreal Anti-VEGF Therapy in a Tertiary Care Center in Eastern India. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3728.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze the indications for anti-VEGF injections in a tertiary care center over a two-year period.
Retrospective observational case series. Data collected for indications of intra-vitreal anti-VEGF therapy between October, 2006 and September, 2008 by three independently practicing retina specialists in a tertiary care center in eastern India.
A total of 324 patients were given intra-vitreal anti-VEGF injections (bevacizumab, ranibizumab and pegaptanib) over the two-year period. Bevacizumab was given to 88.2% (n=289) patients. The indications included choroidal neovascular membrane (CNVM, n=83; 28.7%), venous occlusions (n=79; 27.3 %), proliferative diabetic retinopathy (PDR, n=70; 24.2%), diabetic macular edema (DME, n=26; 8.9%), and others (n=31; 10.7%). Ranibizumab was given to 7.3% (n=24) patients and for the following indications - CNVM (n=20; 83.3%), venous occlusions (n=2; 8.3%), DME (n=1; 4.2%) and others (n=1; 4.2%). The indications for pegaptanib (n=15, 4.6%), included DME (n=10; 66.7%), venous occlusions (n=4; 26.7%) and others (n=1; 6.7%).
The indications for use of anti VEGF intravitreral therapy is as per the current literature though preferential use of bevacizumab was both physician and patient economy driven.
This PDF is available to Subscribers Only